1165 related articles for article (PubMed ID: 32928094)
81. A pH-responsive nano-carrier with mesoporous silica nanoparticles cores and poly(acrylic acid) shell-layers: fabrication, characterization and properties for controlled release of salidroside.
Peng H; Dong R; Wang S; Zhang Z; Luo M; Bai C; Zhao Q; Li J; Chen L; Xiong H
Int J Pharm; 2013 Mar; 446(1-2):153-9. PubMed ID: 23395877
[TBL] [Abstract][Full Text] [Related]
82. Advances in regulating physicochemical properties of mesoporous silica nanocarriers to overcome biological barriers.
Wang Y; Gou K; Guo X; Ke J; Li S; Li H
Acta Biomater; 2021 Mar; 123():72-92. PubMed ID: 33454385
[TBL] [Abstract][Full Text] [Related]
83. Preparation and identification of multifunctional mesoporous silica nanoparticles for in vitro and in vivo dual-mode imaging, theranostics, and targeted tracking.
Chan MH; Lin HM
Biomaterials; 2015 Apr; 46():149-58. PubMed ID: 25678124
[TBL] [Abstract][Full Text] [Related]
84. Biosafety of mesoporous silica nanoparticles; towards clinical translation.
Lérida-Viso A; Estepa-Fernández A; García-Fernández A; Martí-Centelles V; Martínez-Máñez R
Adv Drug Deliv Rev; 2023 Oct; 201():115049. PubMed ID: 37573951
[TBL] [Abstract][Full Text] [Related]
85. An optimized mesoporous silica nanosphere-based carrier system with chemically removable Au nanoparticle caps for redox-stimulated and targeted drug delivery.
Zhang L; Wei F; Al-Ammari A; Sun D
Nanotechnology; 2020 Nov; 31(47):475102. PubMed ID: 32413886
[TBL] [Abstract][Full Text] [Related]
86. Reversibly-regulated drug release using poly(tannic acid) fabricated nanocarriers for reduced secondary side effects in tumor therapy.
Chen C; Ma T; Tang W; Wang X; Wang Y; Zhuang J; Zhu Y; Wang P
Nanoscale Horiz; 2020 Jun; 5(6):986-998. PubMed ID: 32322871
[TBL] [Abstract][Full Text] [Related]
87. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.
Ali OM; Bekhit AA; Khattab SN; Helmy MW; Abdel-Ghany YS; Teleb M; Elzoghby AO
Colloids Surf B Biointerfaces; 2020 Apr; 188():110824. PubMed ID: 32023511
[TBL] [Abstract][Full Text] [Related]
88. Mesoporous Silica Nanoparticles for Targeting Subcellular Organelles.
Gisbert-Garzarán M; Lozano D; Vallet-Regí M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353212
[TBL] [Abstract][Full Text] [Related]
89. Mesoporous silica nanoparticles: An emerging approach in overcoming the challenges with oral delivery of proteins and peptides.
Pamshong SR; Bhatane D; Sarnaik S; Alexander A
Colloids Surf B Biointerfaces; 2023 Dec; 232():113613. PubMed ID: 37913702
[TBL] [Abstract][Full Text] [Related]
90. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
[TBL] [Abstract][Full Text] [Related]
91. Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function.
Pasqua L; Leggio A; Sisci D; Andò S; Morelli C
Mini Rev Med Chem; 2016; 16(9):743-53. PubMed ID: 26996622
[TBL] [Abstract][Full Text] [Related]
92. Meta-Analysis of Efficacy of Chemotherapy Delivered by Mesoporous Silica Nanoparticles to Tumor-Bearing Mice.
McGoron A
Crit Rev Biomed Eng; 2020; 48(6):327-418. PubMed ID: 33641279
[TBL] [Abstract][Full Text] [Related]
93. Morin Hydrate Encapsulation and Release from Mesoporous Silica Nanoparticles for Melanoma Therapy.
Cunha C; Marinheiro D; Ferreira BJML; Oliveira H; Daniel-da-Silva AL
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375331
[TBL] [Abstract][Full Text] [Related]
94. Targeted Stimuli-Responsive Mesoporous Silica Nanoparticles for Bacterial Infection Treatment.
Colilla M; Vallet-Regí M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33203098
[TBL] [Abstract][Full Text] [Related]
95. Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment.
Rosenholm JM; Sahlgren C; Lindén M
Curr Drug Targets; 2011 Jul; 12(8):1166-86. PubMed ID: 21443474
[TBL] [Abstract][Full Text] [Related]
96. How Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature.
Porrang S; Davaran S; Rahemi N; Allahyari S; Mostafavi E
Int J Nanomedicine; 2022; 17():1803-1827. PubMed ID: 35498391
[TBL] [Abstract][Full Text] [Related]
97. The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles.
Chowdhury MA
Curr Drug Deliv; 2016; 13(6):839-56. PubMed ID: 26638978
[TBL] [Abstract][Full Text] [Related]
98. Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications.
Kankala RK; Han YH; Xia HY; Wang SB; Chen AZ
J Nanobiotechnology; 2022 Mar; 20(1):126. PubMed ID: 35279150
[TBL] [Abstract][Full Text] [Related]
99. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy.
Mekaru H; Lu J; Tamanoi F
Adv Drug Deliv Rev; 2015 Dec; 95():40-9. PubMed ID: 26434537
[TBL] [Abstract][Full Text] [Related]
100. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs.
Maleki A; Kettiger H; Schoubben A; Rosenholm JM; Ambrogi V; Hamidi M
J Control Release; 2017 Sep; 262():329-347. PubMed ID: 28778479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
